You are here

Selected publications

2019

1. Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.

LaBranche CC, Henderson R, Hsu A, Behrens S, Chen X, Zhou T, Wiehe K, Saunders KO, Alam SM, Bonsignori M, Borgnia MJ, Sattentau QJ, Eaton A, Greene K, Gao H, Liao HX, Williams WB, Peacock J, Tang H, Perez LG, Edwards RJ, Kepler TB, Korber BT, Kwong PD, Mascola JR, Acharya P, Haynes BF, Montefiori DC.

PLoS Pathog. 2019 15:e1008026.

 

2018

1. Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. 

Schiffner T, Pallesen J, Russell RA, Dodd J, de Val N, LaBranche CC, Montefiori D, Tomaras GD, Shen X, Harris SL, Moghaddam AE, Kalyuzhniy O, Sanders RW, McCoy LE, Moore JP, Ward AB, Sattentau QJ.  

PLoS Pathog. 2018. 14:e1006986.

 

2. RNA Helicase DDX1 Converts RNA G-Quadruplex Structures into R-Loops to Promote IgH Class Switch Recombination.

Ribeiro de Almeida C, Dhir S, Dhir A, Moghaddam AE, Sattentau Q, Meinhart A, Proudfoot NJ.

Mol Cell. 2018 70:650-662.e8.

 

3. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2018 Nov 5;14(11):e1007431. 

 

2017

1. Astrocytes Resist HIV-1 Fusion but Engulf Infected Macrophage Material.

Russell RA, Chojnacki J, Jones DM, Johnson E, Do T, Eggeling C, Padilla-Parra S, Sattentau QJ.

Cell Reports 2017 18: 1473-1483.

 

2. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.

Medina-Ramírez M, Sanders RW, Sattentau QJ.

Curr Opin HIV AIDS. 2017 12:241-249.

 

3. Efferocytosis of Pathogen-Infected Cells.

Karaji N, Sattentau QJ.

Front Immunol. 2017 Dec 22;8:1863.

 

2016

1. Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens.

Schiffner T, de Val N, Russell RA, de Taeye SW, de la Pena AT, Ozorowski G, Kim HJ, Nieusma T, Brod F, Cupo A, Sanders RW, Moore JP, Ward AB, Sattentau, QJ 

J. Virol. 2016 90: 813-828.

 

2. Macrophages and HIV-1: An Unhealthy Constellation.

Sattentau QJ, Stevenson M.

Cell Host Microbe. 2016 19:304-10.

 

3. Sterile inflammation induced by Carbopol elicits robust adaptive immune responses in the absence of pathogen-associated molecular patterns.

Gartlan KH, Krashias G, Wegmann F, Hillson WR, Scherer EM, Greenberg PD, Eisenbarth SC, Moghaddam AE, Sattentau QJ.

Vaccine. 2016 34:2188-96.

 

2015

1. The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice.

Wegmann F, Moghaddam AE, Schiffner T, Gartlan KH, Powell TJ, Russell RA, Baart M, Carrow EW, Sattentau QJ.

Clin Vaccine Immunol. 2015 Sep;22(9):1004-12.

 

2. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.

Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, Georgiev IS, Gindin T, Peng HP, Yang AS; NISC Comparative Sequencing Program, Mullikin JC, Gray MD, Stamatatos L, Burton DR, Koff WC, Cohen MS, Haynes BF, Casazza JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West AP Jr, Bjorkman PJ, Scheid JF, Nussenzweig MC, Shapiro L, Mascola JR, Kwong PD.

Cell. 2015 Jun 4;161(6):1280-92

 

3. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.

Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, Zhou M, Hemashettar G, Bachler BC, Forthal DN, Villinger F, Sattentau QJ, Weiss RA, Agatic G, Corti D, Lanzavecchia A, Heeney JL, Ruprecht RM.

Vaccine. 2015 Apr 21;33(17):2086-95.

 

2014

1. Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques.

Bowles EJ, Schiffner T, Rosario M, Needham GA, Ramaswamy M, McGouran J, Kessler B, LaBranche C, McMichael AJ, Montefiori D, Sattentau QJ, Hanke T, Stewart-Jones GB.

PLoS One. 2014 Dec 9;9(12):e114709

 

2. Macrophage infection via selective capture of HIV-1-infected CD4+ T cells.

Baxter AE, Russell RA, Duncan CJ, Moore MD, Willberg CB, Pablos JL, Finzi A, Kaufmann DE, Ochsenbauer C, Kappes JC, Groot F, Sattentau QJ.

Cell Host Microbe. 2014 Dec 10;16(6):711-21.

 

3. Dry roasting enhances peanut-induced allergic sensitization across mucosal and cutaneous routes in mice.

Moghaddam AE, Hillson WR, Noti M, Gartlan KH, Johnson S, Thomas B, Artis D, Sattentau QJ.

J Allergy Clin Immunol. 2014 Dec;134(6):1453-6.

 

4. Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens.

Sheppard NC, Brinckmann SA, Gartlan KH, Puthia M, Svanborg C, Krashias G, Eisenbarth SC, Flavell RA, Sattentau QJ, Wegmann F.

Int Immunol. 2014 Oct;26(10):531-8.

 

5. Immunogen design to focus the B-cell repertoire.

Sattentau QJ.

Curr Opin HIV AIDS. 2014 May;9(3):217-23.

 

6. Exposure to food allergens through inflamed skin promotes intestinal food allergy through the thymic stromal lymphopoietin-basophil axis.

Noti M, Kim BS, Siracusa MC, Rak GD, Kubo M, Moghaddam AE, Sattentau QJ, Comeau MR, Spergel JM, Artis D.

J Allergy Clin Immunol. 2014 May;133(5):1390-9

 

7. High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.

Duncan CJ, Williams JP, Schiffner T, Gärtner K, Ochsenbauer C, Kappes J, Russell RA, Frater J, Sattentau QJ.

J Virol. 2014 Feb;88(4):2025-34.

 

2013

1. Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies.

Schiffner T, Sattentau QJ, Duncan CJ.

Vaccine. 2013 Dec 2;31(49):5789-97.

 

2. Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils.

Smalls-Mantey A, Connors M, Sattentau QJ.

PLoS One. 2013 Sep 10;8(9):e74858. 

 

13. High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy.

Duncan CJ, Russell RA, Sattentau QJ.

AIDS. 2013 Sep 10;27(14):2201-6.

 

3. Attachment factors.

Jolly CL, Sattentau QJ.

Adv Exp Med Biol. 2013;790:1-23.

 

4. Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis.

Noti M, Wojno ED, Kim BS, Siracusa MC, Giacomin PR, Nair MG, Benitez AJ, Ruymann KR, Muir AB, Hill DA, Chikwava KR, Moghaddam AE, Sattentau QJ, Alex A, Zhou C, Yearley JH, Menard-Katcher P, Kubo M, Obata-Ninomiya K, Karasuyama H, Comeau MR, Brown-Whitehorn T, de Waal Malefyt R, Sleiman PM, Hakonarson H, Cianferoni A, Falk GW, Wang ML, Spergel JM, Artis D.

Nat Med. 2013 Aug;19(8):1005-13.

 

5. Development of prophylactic vaccines against HIV-1.

Schiffner T, Sattentau QJ, Dorrell L.

Retrovirology. 2013 Jul 17;10:72.

 

6. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.

Schiffner T, Kong L, Duncan CJ, Back JW, Benschop JJ, Shen X, Huang PS, Stewart-Jones GB, DeStefano J, Seaman MS, Tomaras GD, Montefiori DC, Schief WR, Sattentau QJ.

J Virol. 2013 Sep;87(18):10163-72.

 

7. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.

Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal DN, Sattentau QJ, Villinger F, Corti D, Ruprecht RM; CAVD Project Group.

AIDS. 2013 Jun 1;27(9):F13-20.

 

8. The HIV-1-containing macrophage compartment: a perfect cellular niche?

Tan J, Sattentau QJ.

Trends Microbiol. 2013 Aug;21(8):405-12.

 

9. Multiple proviral integration events after virological synapse-mediated HIV-1 spread.

Russell RA, Martin N, Mitar I, Jones E, Sattentau QJ.

Virology. 2013 Aug 15;443(1):143-9.

 

10. Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.

Sattentau QJ.

Vaccines. 2013 Oct 28;1(4):497-512

 

2012

1. Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.

Kong L, Sattentau QJ.

J AIDS Clin Res. 2012;S8:3. 

 

2. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens.

Wegmann F, Gartlan KH, Harandi AM, Brinckmann SA, Coccia M, Hillson WR, Kok WL, Cole S, Ho LP, Lambe T, Puthia M, Svanborg C, Scherer EM, Krashias G, Williams A, Blattman JN, Greenberg PD, Flavell RA, Moghaddam AE, Sheppard NC, Sattentau QJ.

Nat Biotechnol. 2012 Sep;30(9):883-8.

 

3. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.

Lai RP, Seaman MS, Tonks P, Wegmann F, Seilly DJ, Frost SD, LaBranche CC, Montefiori DC, Dey AK, Srivastava IK, Sattentau QJ, Barnett SW, Heeney JL.

PLoS One. 2012;7(4):e35083.